Back to Search
HAVISHAKRISHNA SARMA, DO
DO
Internal Medicine Physician
NPI: 1992934020IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
02003960A(IN)
CMS Specialties
PrimaryINTERNAL MEDICINE
Education
LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE, ERIE
Class of 2009
Research & Publications (20)
Modulation of morphological changes of endometrial surface epithelium by administration of composite root extract in albino rat.
PMID 11024229·Contraception·2000
7-preclinical
Effects of composite root extract on histological structures of graffian follicle and endometrial epithelium in albino rat.
PMID 10906505·Contraception·2000
7-preclinical
Preparation of 166Ho-oxine-lipiodol and its preliminary bioevaluation for the potential application in therapy of liver cancer.
PMID 19282794·Nucl Med Commun·2009
7-preclinical
166Ho-labeled hydroxyapatite particles: a possible agent for liver cancer therapy.
PMID 19216630·Cancer Biother Radiopharm·2009
7-preclinical
Bioevaluation of (90)Y-labeled particles in animal model of arthritis.
PMID 19437098·Ann Nucl Med·2009
7-preclinical
(170)Tm-EDTMP: a potential cost-effective alternative to (89)SrCl(2) for bone pain palliation.
PMID 19520297·Nucl Med Biol·2009
7-preclinical
Comparative studies of 177Lu-EDTMP and 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis.
PMID 18372188·Appl Radiat Isot·2008
7-preclinical
Influence of iron and chelator on siderophore production in Frankia strains nodulating Hippophae salicifolia D. Don.
PMID 18383221·J Basic Microbiol·2008
8-other
177Lu-EDTMP: a viable bone pain palliative in skeletal metastasis.
PMID 18454689·Cancer Biother Radiopharm·2008
7-preclinical
Preparation and preliminary studies on 177Lu-labeled hydroxyapatite particles for possible use in the therapy of liver cancer.
PMID 18589303·Nucl Med Biol·2008
7-preclinical
Synthesis and bio-evaluation of a new fatty acid derivative for myocardial imaging.
PMID 18701306·Bioorg Med Chem·2008
4-observational
On the isolation and evaluation of a novel unsubstituted 5-nitroimidazole derivative as an agent to target tumor hypoxia.
PMID 18774708·Bioorg Med Chem Lett·2008
7-preclinical
Preparation and in-vivo evaluation of (188)Re(CO)(3)-colchicine complex for use as tumor-targeting agent.
PMID 19111049·Cancer Biother Radiopharm·2008
7-preclinical
Synthesis of 99mTc-nitrido heterocomplex of piperidine and in vitro and in vivo evaluation of its affinity for sigma receptors.
PMID 18298327·Cancer Biother Radiopharm·2008
7-preclinical
Preparation and evaluation of a new radiopharmaceutical for radiosynovectomy, 111Ag-labelled hydroxyapatite (HA) particles.
PMID 17951062·Appl Radiat Isot·2008
7-preclinical
Bioevaluation studies of 32P incorporated mould brachytherapy sources for potential application in treatment of superficial tumors.
PMID 18753825·Nucl Med Commun·2008
7-preclinical
Radiation-induced incidence of thymic lymphoma in mice and its prevention by antioxidants.
PMID 18197825·J Environ Pathol Toxicol Oncol·2007
7-preclinical
Preparation and preliminary biological evaluation of a novel 109Pd labeled porphyrin derivative for possible use in targeted tumor therapy.
PMID 17372569·Q J Nucl Med Mol Imaging·2007
7-preclinical
Comparative evaluation of heating ability and biocompatibility of different ferrite-based magnetic fluids for hyperthermia application.
PMID 16924619·J Biomed Mater Res B Appl Biomater·2007
4-observational
Evaluation of 99mTc(CO)3 complex of 2-methyl-5-nitroimidazole as an agent for targeting tumor hypoxia.
PMID 16949291·Bioorg Med Chem·2006
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2640 HAMSTROM RD
PORTAGE, IN 46368 - Phone
- (219) 762-9523
Quick Facts
- NPI
- 1992934020
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 17
- Publications
- 20
Are you this provider?
Claim Your Profile